Reduced-Intensity Therapy for Early-Stage Hodgkin Lymphoma

Reduced-cycle chemotherapy plus lower-dose radiotherapy was highly effective in patients with stage I or II disease and favorable prognoses.

The use of combined-modality therapy — doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT) — yields a high cure rate for patients with stage I or II Hodgkin lymphoma (HL). However, each of these modalities poses risks for acute and delayed toxicities. At the American Society of Hematology 2009 meeting, the German Hodgkin Study Group reported preliminary results of a multicenter trial (HD10) showing that therapy de-escalation minimized treatment-related complications yet retained high cure rates in early-stage HL patients with favorable clinical features (JW Oncol Hematol Jan 12 2010).

The same investigators now report further outcomes in 1190 patients (median age, 36; range, 16–75) from th…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee